Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Free Cash Flow: 2018-2024

Historic Free Cash Flow for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$266.9 million.

  • Phathom Pharmaceuticals' Free Cash Flow rose 77.77% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.4 million, marking a year-over-year increase of 9.02%. This contributed to the annual value of -$266.9 million for FY2024, which is 91.72% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Free Cash Flow of -$266.9 million as of FY2024, which was down 91.72% from -$139.2 million recorded in FY2023.
  • Over the past 5 years, Phathom Pharmaceuticals' Free Cash Flow peaked at -$70.7 million during FY2020, and registered a low of -$266.9 million during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$147.6 million (2022), whereas its average is -$184.6 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 110.36% in 2021, then rose by 5.66% in 2023.
  • Over the past 5 years, Phathom Pharmaceuticals' Free Cash Flow (Yearly) stood at -$70.7 million in 2020, then plummeted by 110.36% to -$148.8 million in 2021, then grew by 0.82% to -$147.6 million in 2022, then rose by 5.66% to -$139.2 million in 2023, then slumped by 91.72% to -$266.9 million in 2024.